STOCK TITAN

Ocugen Inc - OCGN STOCK NEWS

Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.

Ocugen, Inc. (NASDAQ: OCGN) is a pioneering biotechnology company that focuses on discovering, developing, and commercializing novel gene and cell therapies, as well as vaccines aimed at improving health and offering hope to patients worldwide. The company's innovative efforts are concentrated on addressing rare and underserved ocular disorders.

Ocugen's core business revolves around a robust clinical pipeline which includes:

  • OCU400: A groundbreaking gene-agnostic modifier gene therapy for retinitis pigmentosa (RP), currently in Phase 3 clinical trials. It leverages the nuclear hormone receptor gene NR2E3 to reset altered cellular gene networks and improve retinal health.
  • OCU410: A potential one-time gene therapy for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). This therapy targets multiple pathways involved in the disease, including lipid metabolism, inflammation, oxidative stress, and the complement system.
  • OCU410ST: Another modifier gene therapy in Phase 1/2 clinical trials for Stargardt disease, the most common form of inherited macular degeneration. It utilizes the AAV delivery platform for the RORA gene to regulate pathways linked to the disease.

Recent milestones include positive feedback from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for the OCU400 Phase 3 liMeliGhT clinical trial, as well as the inclusion of Ocugen in the Russell 3000® Index, highlighting its market presence and growth potential.

Ocugen's commitment to innovative therapies is evident through its modifier gene therapy platforms designed to fulfill unmet medical needs related to inherited retinal diseases such as RP, Leber congenital amaurosis, and Stargardt disease. Additionally, the company is advancing research in infectious diseases to bolster public health and orthopedic diseases to meet unmet medical needs.

For the latest updates and detailed information about Ocugen, Inc., visit their official website at www.ocugen.com and follow them on X and LinkedIn.

Rhea-AI Summary

Ocugen, Inc. (OCGN) announced that its R&D head, Arun Upadhyay, PhD, will present pre-clinical data on OCU410, a modifier gene therapy candidate for Dry Age-related Macular Degeneration (Dry AMD), at the 2nd Annual Dry AMD Therapeutic Development conference on October 20, 2021. OCU410 targets the RORA receptor, which plays a crucial role in several physiological functions affecting Dry AMD, a condition impacting approximately 196 million people worldwide. The therapy is expected to enter clinical trials in 2022, following a collaboration with CanSinoBIO for its development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences clinical trial
-
Rhea-AI Summary

Ocugen (NASDAQ: OCGN) announced the approval of stock options for 48,800 shares and restricted stock units (RSUs) covering 8,200 shares to three new employees as of October 16, 2021. The stock options, with a ten-year term, have an exercise price of $8.66 per share, equal to the closing stock price on the grant date. The options and RSUs will vest annually over three years, contingent on continued employment. This grant is made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ocugen, a biopharmaceutical company (NASDAQ: OCGN), announced that CEO Dr. Shankar Musunuri will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8 a.m. ET. He will discuss the company’s investigational COVID-19 vaccine COVAXIN™, co-developed with Bharat Biotech, and its innovative modifier gene therapy platform aimed at treating retinal diseases. The presentation will be accessible live and later on Ocugen's Investor Relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
Rhea-AI Summary

On September 16, 2021, Ocugen approved the grant of stock options for 137,250 shares and restricted stock units (RSUs) for 23,000 shares to seven employees as inducements for employment. The stock options have a ten-year term with an exercise price of $7.54, set at the common stock's closing price on the grant date. Both the stock options and RSUs vest over three years, contingent on the employees' continued service. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and were issued outside of Ocugen's 2019 Equity Incentive Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
none
-
Rhea-AI Summary

Ocugen, a biopharmaceutical company (NASDAQ: OCGN), announced its participation in upcoming investor conferences: Citi’s 16th Annual BioPharma Virtual Conference from September 8-10, 2021, and the H.C. Wainwright Global Investment Conference from September 13-15, 2021.

Dr. Shankar Musunuri will present at Citi's conference, while CFO Sanjay Subramanian will present at H.C. Wainwright. They will discuss the co-development of COVAXIN™, a COVID-19 vaccine, and advancements in Ocugen's gene therapy platform targeting retinal diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences
-
Rhea-AI Summary

Ocugen, Inc. (NASDAQ: OCGN) announced the approval of stock options for 84,000 shares and restricted stock units (RSUs) for 14,100 shares to five new employees. These options have a ten-year term with an exercise price of $7.06 per share, effective August 16, 2021. The vesting will occur in equal annual installments over three years. This grant was made as a material inducement for employment, aligning with Nasdaq listing regulations. Ocugen is engaged in developing gene therapies for blindness diseases and COVID-19 vaccine candidates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
none
Rhea-AI Summary

Ocugen reports significant progress in its pipeline with the completion of its regulatory submission for COVAXIN™ to Health Canada and ongoing FDA discussions. The company achieved a $115.8 million cash position, up from $24.2 million at year-end 2020. Major financials include research and development expenses of $18.9 million driven by a $15 million payment to Bharat Biotech, and a net loss per share of $0.13. The organization also welcomed new senior management and expanded its workforce to support growth in clinical development and commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced a conference call to discuss its Q2 2021 financial results and provide a business update on August 6, 2021, at 8:30 a.m. ET. A pre-market earnings announcement will precede the call. Investors can participate via dial-in or webcast. Ocugen focuses on developing gene therapies for blindness and a COVID-19 vaccine, notably co-developing the COVAXIN™ vaccine. The release highlights forward-looking statements and encourages reviewing risk factors in their SEC filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
conferences earnings
-
Rhea-AI Summary

Ocugen, Inc. (NASDAQ: OCGN) announced the approval of stock options for 150,750 shares and restricted stock units (RSUs) for 25,250 shares to seven new employees as of July 16, 2021. The stock options come with a ten-year term at an exercise price of $6.66 per share, aligning with the closing price on the grant date. Both the options and RSUs will vest in equal annual installments over three years, contingent on continued service. This grant aims to incentivize new talent in line with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.91%
Tags
none
Rhea-AI Summary

Ocugen, Inc. (OCGN) announced the initiation of a rolling submission to Health Canada for COVAXIN™, its COVID-19 vaccine candidate developed in collaboration with Bharat Biotech. This decision follows positive Phase 3 clinical trial results showcasing efficacy and safety among nearly 25,800 participants. The rolling submission allows for ongoing review of data as it becomes available, potentially speeding up the approval process. COVAXIN™ has demonstrated a strong safety profile and is currently administered under emergency authorizations in 13 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
none

FAQ

What is the current stock price of Ocugen (OCGN)?

The current stock price of Ocugen (OCGN) is $0.68 as of February 21, 2025.

What is the market cap of Ocugen (OCGN)?

The market cap of Ocugen (OCGN) is approximately 203.7M.

What does Ocugen, Inc. specialize in?

Ocugen specializes in discovering, developing, and commercializing novel gene and cell therapies, as well as vaccines aimed at improving health and offering hope to patients worldwide.

What are Ocugen's key projects?

Ocugen's key projects include OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy, and OCU410ST for Stargardt disease. These therapies focus on modifying gene functions to treat retinal diseases.

What recent achievements has Ocugen accomplished?

Recent achievements include EMA and FDA clearance for the OCU400 Phase 3 clinical trial and inclusion in the Russell 3000® Index, signifying its market relevance and growth potential.

How does OCU400 work?

OCU400 is a gene-agnostic modifier gene therapy that uses the NR2E3 gene to reset altered cellular gene networks, aiming to improve retinal health in patients with retinitis pigmentosa.

What is the significance of Ocugen's modifier gene therapy platform?

Ocugen's modifier gene therapy platform is designed to treat multiple retinal diseases with a single product by addressing broader genetic conditions, offering hope to patients with complex inherited retinal disorders.

What are the target conditions for OCU410?

OCU410 targets geographic atrophy (GA), an advanced stage of dry age-related macular degeneration, by addressing multiple pathways involved in the disease such as lipid metabolism, inflammation, and oxidative stress.

How does OCU410ST aim to treat Stargardt disease?

OCU410ST uses the RORA gene delivered via an AAV platform to regulate pathways linked to Stargardt disease, targeting factors like oxidative stress and inflammation to preserve photoreceptor cells in the retina.

What is the impact of Ocugen's inclusion in the Russell 3000® Index?

Inclusion in the Russell 3000® Index enhances Ocugen's visibility within the investment community, supports long-term shareholder value, and broadens its shareholder base.

What steps has Ocugen taken to ensure the success of its clinical therapy programs?

Ocugen has received regulatory clearances for pivotal clinical trials, engaged in continuous safety and efficacy assessments, and is leveraging strategic partnerships to support its entire pipeline.

Where can I learn more about Ocugen's latest news and developments?

For the latest news and updates about Ocugen, visit their official website at www.ocugen.com and follow them on X and LinkedIn.
Ocugen Inc

Nasdaq:OCGN

OCGN Rankings

OCGN Stock Data

203.72M
287.58M
1.27%
27.53%
19.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MALVERN